GENESIS Pharma engages in the sales and marketing of a unique portfolio of branded biopharmaceutical products principally within the specialty therapeutic areas of Oncology, Hematology, Nephrology and the Central Nervous System (CNS).

Many of these products treat rare chronic or life-threatening diseases and most of them address previously unmet or underserved clinical needs.

Products marketed and sold by GENESIS Pharma are:

ARANESP^® (Darbepoetin alpha)
Amgen

AVONEX^® (Interferon Beta-1a)
Biogen Idec

FERINJECT (Intravenous Iron Carboxymaltose)
Vifor

FOSRENOL^® (Lanthanum carbonate)
Shire

GLIADEL^® Wafer (polifeprosan 20 with carmustine implant)
Eisai

GRANULOKINE^® (Filgrastim)
Amgen

KEPIVANCE^® (Palifermin)
Biovitrum

KINERET^® (Anakinra)
Biovitrum

MEZAVANT (Mesalazine)
Shire

MIMPARA^® (Cinacalcet)
Amgen

MODIODAL^® (Modafinil)
Cephalon

NEULASTA^® (Pegfilgrastim)
Amgen

PROLEUKIN^® (Aldesleukin)
Novartis

REFLUDAN ^® (Lepirudin)
Celgene

REVLIMID^® (Lenalidomide)
Celgene

THALIDOMIDE CELGENE^® (Thalidomide)
Celgene

TYSABRI^®(Natalizumab)
Biogen Idec - Elan Pharmaceuticals, Inc.

VENOFER^® (IV Iron)
Vifor

VIDAZA (Azacitidine)
Celgene

XAGRID^® (Anagrelide Hydrochloride)
Shire

Yondelis^®(Trabectedin)
Pharmamar

Additionally, the following biopharmaceutical products in GENESIS Pharma portfolio have received marketing authorization and are currently in the pre-marketing phase:

MEPACT (L-MTP-PE)
IDM Pharma